Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jul 18, 2023 1:30pm
129 Views
Post# 35546376

RE:RE:RE:RE:RE:Pfizer partners with startup Flagship valued at US$7 Billion

RE:RE:RE:RE:RE:Pfizer partners with startup Flagship valued at US$7 BillionNo one said they did. The purpose of this subject was to demonstrate that Big Pharma is prepared to  spend Billion$$ and is having to reach further upstream in the R&D process in an effort to gain new assets to help stave off the looming patent cliff that they face and replenish their dwindling product portfolios. I can't seek how some on this message board keep missing this overwhelming issue for Big Pharma.. 

Consequently, Big Pharma will have to increasingly look at negotiating US$ 10 Billion to US$25 Billion M&A valuations to acquire late stage high-vale assets like ONCY's pelareorep, and still avoid FTC scrutiny.  A US$10 Billion to US$15 Billion acquistion of ONCY will do both.
<< Previous
Bullboard Posts
Next >>